EP1100475A1 - Use of drug-loaded nanoparticles for the treatment of cancers - Google Patents

Use of drug-loaded nanoparticles for the treatment of cancers

Info

Publication number
EP1100475A1
EP1100475A1 EP99926509A EP99926509A EP1100475A1 EP 1100475 A1 EP1100475 A1 EP 1100475A1 EP 99926509 A EP99926509 A EP 99926509A EP 99926509 A EP99926509 A EP 99926509A EP 1100475 A1 EP1100475 A1 EP 1100475A1
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
treatment
mammal
cancer
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99926509A
Other languages
German (de)
French (fr)
Inventor
Bernhard A. Sabel
Jörg KREUTER
Svetlana Gelperina
Ulrike SCHRÖDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoPharm AG
Original Assignee
Medinova Medical Consulting GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinova Medical Consulting GmbH filed Critical Medinova Medical Consulting GmbH
Publication of EP1100475A1 publication Critical patent/EP1100475A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of drug-loaded nanoparticles for preparing a medicament for the treatment of cancer, particularly for the treatment of cancer in the brain, even more particularly for the treatment of brain cancer in humans.
  • the invention also relates to a process for the treatment of brain cancer, particularly for the treatment of brain cancer in humans, by ad ⁇ iinistering an effective amount of nanoparticles containing a substance which has effect in the cancer treatment or has immunosuppressive effects.
  • blood brain barrier refers to the bbb in the narrower sense, i. e. in the sense this term is used usually by a person skilled in the medical field, as well as to the blood spinal barrier and blood retina barrier.
  • nanoparticles prepared in accordance with teachings of the prior art, particularly of the above two Patent Applications may be loaded with a substance having effect in the treatment of cancers, particularly having effect in the treatment of cancers in the brain, for example in humans, in an effective amount and may then be coated with a suitable surfactant so as to allow that drug-loaded nanoparticles to pass across the bbb and to deliver the effective drug to the site where it may exhibit its anticancer and/or immunosuppressive activity. It was particularly found that, by a suitable selection of the combination drug/surfactant, an effective use of such nanoparticles loaded with the drug and coated with a surfactant in the treatment of cancers, particularly of cancers in the brain, may be pro viced.
  • the invention relates to the use of nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within or on said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the manufacture of a medicament for the treatment of cancer in said mammal.
  • the treatment of cancer is a treatment of cancer in the brain.
  • the brain cancer treatment is a treatment to a human.
  • the terms "cancer” and “tumor(s)” are used in the description and claims in a synonymous manner.
  • the nanoparticles used in the present invention for the cancer treatment are nanoparticles which mainly consist of three major components, i. e. the polymeric material which is used to form a wall either incorporating the drug or physiologically effective substance(s) or containing said substance(s) adsorbed or absorbed thereto, e. g. onto its surface; the physiologically effective substance or substances contained within or on said nanoparticle; and a stabilizer or more than one stabilizer allowing the passage of said nanoparticle across the bbb.
  • the present invention comprises as one of the preferred embodiments the use of said nanoparticles, wherein said nanoparticles comprise particles of said polymeric material having a diameter of below 1,000 nm, preferably of from 1 to 1,000 nm.
  • the invention relates to the use of said nanoparticles, wherein said polymeric material the nanoparticles are consisting of is selected from the group consisting of polyacrylates, polymethacrylates, poly-cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, -dbumin, polystyrenes, poly vinyls, polyacro ⁇ ein, polyglutaraldehydes and derivatives, copolymers and rnixtures thereof.
  • polyacrylates polymethacrylates, poly-cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, -dbumin, polystyrenes, poly vinyls, polyacro ⁇ ein, polyglutaraldehydes and derivatives, copolymers and rnixtures thereof.
  • the nanoparticles according to the invention there is/are provided within or on said nanoparticles (incorporated, absorbed and/or adsorbed) one or more substances which are physiologically effective in the treatment of cancer upon delivery to a mammal.
  • the substances may be a single substance or may be two or even more substances which may act on the human body on a separate route or on a combined route or even synergistic route.
  • said physiologically effective substance(s) to be delivered to said mammal comprise(s) one or more chemotherapeutic agent(s) for the cancer treatment, particularly for the treatment of cancer in the brain of said mammal, more particularly for the treatment of cancer in the human body, i. e. the brain.
  • chemotherapeutic agent(s) for the cancer treatment particularly for the treatment of cancer in the brain of said mammal, more particularly for the treatment of cancer in the human body, i. e. the brain.
  • chemotherapeutic anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural anticancer products, hormones, metal coordination complexes and mixtures thereof.
  • chemotherapeutic anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural anticancer products, hormones, metal coordination complexes and mixtures thereof.
  • nitroso ureas e. g. Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl- CCNU) and Nimustine (ACNU);
  • BCNU Carmustine
  • CCNU Lomustine
  • CCNU Semustine
  • ACNU Nimustine
  • folic acid analogs e. g. Methotrexate
  • - purine analogs e. g. Mercaptopurine and Azathioprine
  • - vinca alkaloids e. g. Vinblastine, Nincristine and Vindesine
  • epipodophyllotoxins e. g. Etoposide and Teniposide
  • antibiotics e. g. Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Bleomycin A2, Mitomycin C and Mitoxantrone;
  • - estrogens e. g. Diethyl stilbestrol
  • - gonadotropin-releasing hormon analogs e. g. Leuprolide, Buserelin and Goserelin
  • antiestrogens e. g. Tamoxifen and Ammoglutethimide
  • a critical component of the nanoparticles used in the present invention is/are the stabilizer(s).
  • only one stabilizer is used whereby a passage of the bbb by said nanoparticles loaded with the anticancer drugs can be afforded in a successful way, and the anticancer drugs in said nanoparticles are directed to the tumor site in the brain in a high concentration.
  • the other critical component of the nanoparticles used in the present invention are the surfactant materials of the coating which materials are belonging to the same group of compounds as the above.
  • the stabilizer may be present in the nanoparticles used in accordance with the present invention as a result of the manufacturing steps either in small remaining amounts or may form the coating allowing the passage of the effective substance(s) across the bbb.
  • the separate coating may be provided.
  • the outside wall of the nanoparticles used in the present invention is coated with the material allowing the passage of the bbb in a surprising manner.
  • the application of the coating or the provision of the stabilizer in such nanoparticles is basically described in the above-mentioned International Patent Applications the disclosures of which are incorporated herein by reference.
  • the material(s) of the stabilizer/ surfactant is/are selected selected from the group consisting of stabilizers/surfactants which allow a passage of said nanoparticles including said physiologically effective substance(s) across the blood brain barrier in said mammal and stabilizers/surfactants which allow a release of said physiologically effective substance(s) from said nanoparticles and a passage of said substance(s) across the blood brain barrier separate from said nanoparticles.
  • said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbates, dextrans, carboxylic acid esters of multifunctional alcohols, polyoxamers, polyoxamines, alkoxylated ethers, alkoxylated esters, alkoxylated mono-, di- and triglycerides, alkoxylated phenols and diphenols, substances of the Genapol R and Bauki R series, metal salts of carboxylic acids, metal salts of alcohol sulfates, and metal salts of sulfosuccinates and mixtures of two or more of said substances.
  • said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 81, polysorbate 85, dextran 12.000, dextran 70,000, fatty acid esters of glycerol and sorbitol as glycerol monostearate, sorbitan monostearate and sorbitan monooleate, polyoxamer 188 (Pluronic R F68), ethoxylated ethers, ethoxylated esters, ethoxylated triglycerides, ethoxylated phenols and diphenols, metal salts of fatty acids and of fatty alcohol sulfates, more preferably the sodium salts of fatty acids and of fatty alcohol sulfates
  • the most preferred stabilizers/surfactant materials are selected from the group consisting of polysorbate 80, polysorbate 85, dextran 12,000 or dextran 70,000 and mixtures thereof and mixtures of said stabilizers with other stabilizers. With the latter compounds, a superior use of the nanoparticles in the anticancer treatment can be achieved, particularly in the treatment of brain cancers in humans.
  • said carrier and/or diluent which is used for the aclministration of the nanoparticles used in the present invention is/are selected from the group consisting of water, physiologically acceptable aqueous solutions containing salts and/or buffers and any other solution acceptable for administration to a mammal.
  • nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the treatment of cancer in said mammal.
  • a process for the treatment of cancer particularly of brain cancer, in mammals, said process comprising the step of administering to said mammals nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, in an amount effective for the treatment of cancer.
  • the administration is an i.v. administration. It is particularly preferred that the treatment is a treatment of brain cancer, e. g. in mammals as for example humans.
  • the invention is further exemplified by the subsequent example which, however, should not be understood to limit the invention.
  • the anti-tumor effect of doxorubicin preparations was tested in rats with an intracranially transplanted glioblastoma 101/8. This tumor is known to have a substantial number of receptors to the epidermal growth factor.
  • mice were treated with 1.5 mg/kg x 3 of doxorubicin which makes a total course dose of 4.5 mg/kg (the total dose for mice is usually 7 to 8 mg/kg).
  • the drugs were administered i/v on the day 2 (48 h after implantation of the tumor), day 5 and day 8 after tumor implantation.
  • Drug preparations were administered as usual in saline or in 1 % Tween R 80 .
  • the suspension was added with 1 % Tween R 80 with stirring. The mixture was incubated for 2 h.

Abstract

The present invention relates to the use of drug-loaded nanoparticles for preparing a medicament for the treatment of cancer, particularly for the treatment of cancer in the brain, even more particularly for the treatment of brain cancer in humans. The invention also relates to a process for the treatment of brain cancer, particularly for the treatment of brain cancer in humans by administering an effective amount of nanoparticles containing a substance which has effect in the cancer treatment or has immunosuppressive effects.

Description

Use of Drug-Loaded Nanoparticles for the Treatment of Cancers
The present invention relates to the use of drug-loaded nanoparticles for preparing a medicament for the treatment of cancer, particularly for the treatment of cancer in the brain, even more particularly for the treatment of brain cancer in humans. The invention also relates to a process for the treatment of brain cancer, particularly for the treatment of brain cancer in humans, by adπiinistering an effective amount of nanoparticles containing a substance which has effect in the cancer treatment or has immunosuppressive effects.
It was reported in the TJ. S. Patent Application S. N. 08/203,326 and the parallel International Patent Application No. PCT/EP 95/00724 (corresponding to WO 95/22963) that drugs may be delivered to the body of rriammals, particularly to the body of humans, and may be transported across the blood brain barrier (furtheron referred to as "bbb") by means of nanoparticles to which drugs are complexed (incorporated, adsorbed or absorbed) and which are surrounded by a coating made of an appropriate surfactant. A similar teaching can be found in the pending International Patent Application No. PCT/EP 97/03099. It was taught in both of said applications that the drug may be an immunosuppressive or anticancer agent. As the appropriate surfactant, there were taught a number of generally and commercially available surfactants as, for example, Polysorbate R 80 or Tween R 80.
It is general knowledge that the non-invasive treatment of cancers in the brain of mammals, particularly in the brain of humans has to rely on very small amounts of immunosuppressive or anticancer medicaments or drugs which are transported to the desired target, i. e. the tumor in the brain. In particular, anticancer agents known to have a high effect in the anticancer treatment do not at all or do not in a sufficiently effective amount pass the blood brain barrier (bbb) and are effective only when delivered directly into the brain. Such a delivery step, however, means a delivery into the skull at a suitable point which is a very complicated and sometimes risky surgery step. The term "blood brain barrier " (bbb) as used herein refers to the bbb in the narrower sense, i. e. in the sense this term is used usually by a person skilled in the medical field, as well as to the blood spinal barrier and blood retina barrier.
It was now surprisingly found that nanoparticles prepared in accordance with teachings of the prior art, particularly of the above two Patent Applications, may be loaded with a substance having effect in the treatment of cancers, particularly having effect in the treatment of cancers in the brain, for example in humans, in an effective amount and may then be coated with a suitable surfactant so as to allow that drug-loaded nanoparticles to pass across the bbb and to deliver the effective drug to the site where it may exhibit its anticancer and/or immunosuppressive activity. It was particularly found that, by a suitable selection of the combination drug/surfactant, an effective use of such nanoparticles loaded with the drug and coated with a surfactant in the treatment of cancers, particularly of cancers in the brain, may be pro viced.
Hence, the invention relates to the use of nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within or on said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the manufacture of a medicament for the treatment of cancer in said mammal.
In a preferred embodiment of the present invention, the treatment of cancer is a treatment of cancer in the brain. In an even more preferred embodiment, the brain cancer treatment is a treatment to a human. The terms "cancer" and "tumor(s)" are used in the description and claims in a synonymous manner. The nanoparticles used in the present invention for the cancer treatment are nanoparticles which mainly consist of three major components, i. e. the polymeric material which is used to form a wall either incorporating the drug or physiologically effective substance(s) or containing said substance(s) adsorbed or absorbed thereto, e. g. onto its surface; the physiologically effective substance or substances contained within or on said nanoparticle; and a stabilizer or more than one stabilizer allowing the passage of said nanoparticle across the bbb.
Although there are basically no limitations with respect to any of the above three components and their combinations, as long as they allow the achievement of the intended goal, the present invention comprises as one of the preferred embodiments the use of said nanoparticles, wherein said nanoparticles comprise particles of said polymeric material having a diameter of below 1,000 nm, preferably of from 1 to 1,000 nm.
In a further preferred embodiment, the invention relates to the use of said nanoparticles, wherein said polymeric material the nanoparticles are consisting of is selected from the group consisting of polyacrylates, polymethacrylates, poly-cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, -dbumin, polystyrenes, poly vinyls, polyacroόein, polyglutaraldehydes and derivatives, copolymers and rnixtures thereof. There is of course no limit with respect to the specific material of the nanoparticles, as long as the material used allows or even promotes the successful transport to and passage across the bbb of the physiologically effective substanc or substances.
In accordance with the present use of the nanoparticles according to the invention, there is/are provided within or on said nanoparticles (incorporated, absorbed and/or adsorbed) one or more substances which are physiologically effective in the treatment of cancer upon delivery to a mammal. The substances may be a single substance or may be two or even more substances which may act on the human body on a separate route or on a combined route or even synergistic route.
In a preferred use according to the present invention, said physiologically effective substance(s) to be delivered to said mammal comprise(s) one or more chemotherapeutic agent(s) for the cancer treatment, particularly for the treatment of cancer in the brain of said mammal, more particularly for the treatment of cancer in the human body, i. e. the brain. Such delivery of anticancer agents to the human brain was very difficult in the prior art, what concerns the effective amounts which could be provided to the site of action of the chemotherapeutic agent; surprisingly, the use of the present invention provides an effective and controllable amount of such substance(s) at the site of their action in an easily administrable composition.
In accordance with the present invention, such a use of said nanoparticles is preferred, wherein said chemotherapeutic anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural anticancer products, hormones, metal coordination complexes and mixtures thereof. There is no restriction concerning the administration of substances of one single group or of more than one of the above groups which, of course, include numerous substances specifically mentioned above. There is only the requirement that these substances may be suitably incorporated into or adsorbed onto or absorbed by said nanoparticles used in the present invention and do not interfere with each other during such a use.
As specific substances for a use in accordance with a preferred embodiment of the invention, there may be mentioned the following substances, without restricting the inventive use to the substances mentioned below: - nitrogen mustards, e. g. Cyclophosphamide, Trofosf amide, Ifosf amide and Chlorambucil;
- nitroso ureas, e. g. Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl- CCNU) and Nimustine (ACNU);
- ethylene imines and memyl-melamines, e. g. Thiotepa;
- folic acid analogs, e. g. Methotrexate;
- pyrimidine analogs, e. g. 5-Fluorouracil and Cytarabine;
- purine analogs, e. g. Mercaptopurine and Azathioprine; - vinca alkaloids, e. g. Vinblastine, Nincristine and Vindesine;
- epipodophyllotoxins, e. g. Etoposide and Teniposide;
- antibiotics, e. g. Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Bleomycin A2, Mitomycin C and Mitoxantrone;
- estrogens, e. g. Diethyl stilbestrol; - gonadotropin-releasing hormon analogs, e. g. Leuprolide, Buserelin and Goserelin;
- antiestrogens, e. g. Tamoxifen and Ammoglutethimide;
- androgens, e. g. Testolactone and Drostanolonproprionate; and
- platinum complexes, e. g. Cisplatin and Carboplatin.
According to the invention, mixtures of the above substances may also be used as long as they result into a successful treatment of cancer, particularly of brain cancer, in mammals as for example in humans. Particularly preferred in the use of the nanoparticles of the pϋresent invention are Doxorubicin and/or Mitoxantrone, since the administration of any of these substances by using nanoparticles results into a successful anticancer treatment, particularly a successful treatment of brain tumors in niammals as for example in humans. In particular, a passage of the bbb by said substance in a therapeutically effective amount was observed, which fact was completely surprising for a skilled person being familiar with the prior art problem of providing a therapeutically effective amount of said anticancer agents in the brain. A critical component of the nanoparticles used in the present invention is/are the stabilizer(s). In a preferred use, only one stabilizer is used whereby a passage of the bbb by said nanoparticles loaded with the anticancer drugs can be afforded in a successful way, and the anticancer drugs in said nanoparticles are directed to the tumor site in the brain in a high concentration. This was not yet possible in the prior art approaches. As a result thereof, the treatment of brain cancers could be considerably improved, and the success rates of the treatment could be increased as well.
The other critical component of the nanoparticles used in the present invention are the surfactant materials of the coating which materials are belonging to the same group of compounds as the above. The stabilizer may be present in the nanoparticles used in accordance with the present invention as a result of the manufacturing steps either in small remaining amounts or may form the coating allowing the passage of the effective substance(s) across the bbb. As an alternative, the separate coating may be provided. As a result, the outside wall of the nanoparticles used in the present invention is coated with the material allowing the passage of the bbb in a surprising manner. The application of the coating or the provision of the stabilizer in such nanoparticles is basically described in the above-mentioned International Patent Applications the disclosures of which are incorporated herein by reference.
In a preferred embodiment of the present inventive use, the material(s) of the stabilizer/ surfactant is/are selected selected from the group consisting of stabilizers/surfactants which allow a passage of said nanoparticles including said physiologically effective substance(s) across the blood brain barrier in said mammal and stabilizers/surfactants which allow a release of said physiologically effective substance(s) from said nanoparticles and a passage of said substance(s) across the blood brain barrier separate from said nanoparticles. It is furthermore preferred that said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbates, dextrans, carboxylic acid esters of multifunctional alcohols, polyoxamers, polyoxamines, alkoxylated ethers, alkoxylated esters, alkoxylated mono-, di- and triglycerides, alkoxylated phenols and diphenols, substances of the Genapol R and Bauki R series, metal salts of carboxylic acids, metal salts of alcohol sulfates, and metal salts of sulfosuccinates and mixtures of two or more of said substances.
Specific examples of said stabilizers and/or surfactants which are used for the coating for the nanoparticles are mentioned below, without restricting the invention to the compounds or groups of compounds mentioned below. Preferably, said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 81, polysorbate 85, dextran 12.000, dextran 70,000, fatty acid esters of glycerol and sorbitol as glycerol monostearate, sorbitan monostearate and sorbitan monooleate, polyoxamer 188 (Pluronic R F68), ethoxylated ethers, ethoxylated esters, ethoxylated triglycerides, ethoxylated phenols and diphenols, metal salts of fatty acids and of fatty alcohol sulfates, more preferably the sodium salts of fatty acids and of fatty alcohol sulfates, even more preferably sodium stearate and sodium lauryl sulfate, and mixtures of two or more of said substances.
The most preferred stabilizers/surfactant materials are selected from the group consisting of polysorbate 80, polysorbate 85, dextran 12,000 or dextran 70,000 and mixtures thereof and mixtures of said stabilizers with other stabilizers. With the latter compounds, a superior use of the nanoparticles in the anticancer treatment can be achieved, particularly in the treatment of brain cancers in humans.
It is an accordance with a further preferred use of the nanoparticles, if said carrier and/or diluent which is used for the aclministration of the nanoparticles used in the present invention is/are selected from the group consisting of water, physiologically acceptable aqueous solutions containing salts and/or buffers and any other solution acceptable for administration to a mammal. In accordance with the invention, there are further provided nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the treatment of cancer in said mammal.
In another aspect of the invention, there is provided a process for the treatment of cancer, particularly of brain cancer, in mammals, said process comprising the step of administering to said mammals nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, in an amount effective for the treatment of cancer.
In a preferred process according to the invention, the administration is an i.v. administration. It is particularly preferred that the treatment is a treatment of brain cancer, e. g. in mammals as for example humans.
The invention is further exemplified by the subsequent example which, however, should not be understood to limit the invention. The anti-tumor effect of doxorubicin preparations was tested in rats with an intracranially transplanted glioblastoma 101/8. This tumor is known to have a substantial number of receptors to the epidermal growth factor.
The animals were treated with 1.5 mg/kg x 3 of doxorubicin which makes a total course dose of 4.5 mg/kg (the total dose for mice is usually 7 to 8 mg/kg).
The drugs were administered i/v on the day 2 (48 h after implantation of the tumor), day 5 and day 8 after tumor implantation.
The experiment was started on 9 to 13 December 1998 and was not yet completed by 20 May 1999 since some of the animals are still alive.
Drug preparations were administered as usual in saline or in 1 % Tween R 80 . For the coating of the nanoparticles loaded with doxorubicin, the suspension was added with 1 % Tween R 80 with stirring. The mixture was incubated for 2 h.
It can be seen from the subsequent tables that in the case that doxorubicin was administered ("Dox"), the rats died after the times (hours, h) given in column 1 of the upper table. In the case of the administration of the drug with Tween 80, most of the rats died, too. As in the first case, all rats died after ac-ministration of Tween 80 coated nanoparticles and doxorubicin-loaded nanoparticles without coating (columns 3 and 4 of the upper table). Only in the case that doxorubicin-loaded nanoparticles were coated with Tween 80, 3 of 8 rats survived.
This result clearly shows that the surfactant-coated nanoparticles were suitable to promote the passage of an effective dose of the anticancer agent doxorubicin across the bbb for a successful anticancer treatment. Survival rate (days) of glioblastoma 101/8 bearing rats after i/v administration of doxorubicin preparations

Claims

C l a i m s
5 1. Use of nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said
10 nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the manufacture of a medicament for the treatment of cancer in said mammal.
15 2. The use according to claim 1 for the treatment of brain cancer in said mammal.
3. The use according to claim 1 or claim 2, wherein said nanoparticles comprise particles of said polymeric material having a diameter of below 1,000 nm, preferably of from 1 to 1,000 nm.
T 0
4. The use according to any of the claims 1 to 3, wherein said polymeric material is selected from the group consisting of polyacrylates, polymethacrylates, poly- cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, albumin, polystyrenes, poly vinyls,
25 polyacrooein, polyglutaraldehydes and derivatives, copolymers and mixtures thereof.
5. The use according to any of the claims 1 to 4, wherein said nanoparticles comprise said physiologically effective substance(s) to be delivered to said mammal in the form adsorbed, absorbed and/or incorporated thereto.
6. The use according to any of the claims 1 to 5, wherein said physiologically effective substance(s) to be delivered to said mammal comprise(s) one or more chemotherapeutic agent(s) for the cancer treatment, preferably alkylating agents, antimetabolites, natural anticancer products, hormones, metal co-ordination complexes and mixtures thereof, more preferably nitrogen mustards, nitroso ureas, ethylene imines and methyl- melamines, folic acid analogs, pyrimidine analogs, purine analogs, vinca alkaloids, epipodophyllotoxins, antibiotics, estrogens, gonadotropin-releasing hormon analogs, antiestrogens, androgens, platinum complexes and mixtures thereof, even more preferred doxorubicin and/or mitoxantrone.
7. The use according to any of the claims 1 to 6, wherein the stabilizer and/or surfactant coating material is selected from the group consisting of stabilizers/surfactants which allow a passage of said nanoparticles including said physiologically effective substance(s) across the blood brain barrier in said mammal and stabilizers/surfactants which allow a release of said physiologically effective substance(s) from said nanoparticles and a passage of said substance(s) across the blood brain barrier separate from said nanoparticles, preferably wherein said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbates, dextrans, carboxylic acid esters of multifunctional alcohols, polyoxamers, polyoxamines, alkoxylated ethers, alkoxylated esters, alkoxylated mono-, di- and triglycerides, alkoxylated phenols and diphenols, substances of the Genapol R and Bauki R series, metal salts of carboxylic acids, metal salts of alcohol sulfates, and metal salts of sulfosuccinates and mixtures of two or more of said substances, more preferably wherein said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbate 20, polysorbate
40, polysorbate 60, polysorbate 80, polysorbate 81, polysorbate 85, dextran 12.000, dextran 70,000, fatty acid esters of glycerol and sorbitol as glycerol monostearate, sorbitan monostearate and sorbitan monooleate, polyoxamer 188 (Pluronic R F68), ethoxylated ethers, ethoxylated esters, ethoxylated triglycerides, ethoxylated phenols and diphenols, metal salts of fatty acids and of fatty alcohol sulfates, more preferably the sodium salts of fatty acids and of fatty alcohol sulfates, even more preferably sodium stearate and sodium lauryl sulfate, and mixtures of two or more of said substances, even more preferably polysorbate 80, polysorbate 85, dextran 12,000 or dextran 70,000 and mixtures thereof and mixtures of the stabilizers/surfactants with other stabilizers/surfactants.
8. The use according to any of the claims 1 to 7, wherein said carrier and/or diluent is/are selected from the group consisting of water, physiologically acceptable aqueous solutions containing salts and/or buffers and any other solution acceptable for administration to a mammal.
9. The use according to any of the claims 1 to 8, wherein the administration is an i. v. administration.
10. The use according to any of the claims 1 to 9, wherein said mammal is a human.
11. Nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after adπtiinistration, for the treatment of cancer in said mammal.
12. A process for the treatment of cancer, particularly of brain cancer, in mammals, said process comprising the step of administering to said mammals nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said πiammal after administration, in an amount effective for the treatment of cancer.
13. The process of claim 12, wherein the administration is an i.v. or i.p. administration.
14. The process according to claim 12 or claim 13, wherein the treatment is a treatment of brain cancer.
EP99926509A 1999-06-02 1999-06-02 Use of drug-loaded nanoparticles for the treatment of cancers Ceased EP1100475A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1999/003838 WO2000074658A1 (en) 1999-06-02 1999-06-02 Use of drug-loaded nanoparticles for the treatment of cancers

Publications (1)

Publication Number Publication Date
EP1100475A1 true EP1100475A1 (en) 2001-05-23

Family

ID=8167319

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99926509A Ceased EP1100475A1 (en) 1999-06-02 1999-06-02 Use of drug-loaded nanoparticles for the treatment of cancers

Country Status (4)

Country Link
EP (1) EP1100475A1 (en)
JP (1) JP2003501379A (en)
AU (1) AU4373499A (en)
WO (1) WO2000074658A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3176097A (en) 1997-06-13 1998-12-30 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
DE10121982B4 (en) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
EP1448174A2 (en) * 2001-09-28 2004-08-25 Solubest Ltd Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
DE60229003D1 (en) * 2002-07-29 2008-10-30 Nanodel Technologies Gmbh NANOPARTICLES FOR DNA DELIVERY TO A TARGET ORGAN
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
KR20080080488A (en) 2005-09-30 2008-09-04 티티아이 엘뷰 가부시키가이샤 Electrode structure for iontophoresis used to administer drug enclosed in nanoparticle and iontophoresis device making use of the same
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DE102005062440B4 (en) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Protein-based carrier system for the resistance of tumor cells
WO2007079193A2 (en) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
EP2072079A1 (en) 2006-10-10 2009-06-24 TTI ellebeau, Inc. Artificial tooth-type iontophoresis device
JP5201763B2 (en) * 2007-02-28 2013-06-05 昇一 城武 Method for producing mixed fine particle capsules comprising particles having different average particle sizes
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
WO2010040173A1 (en) * 2008-10-08 2010-04-15 Commonwealth Scientific And Industrial Research Organisation A method of delivering functional agents across the blood-brain barrier
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
CN103623424B (en) * 2012-08-24 2016-08-03 复旦大学 A kind of brain targeting gene based on polymethacrylates passs release system
CN110198703A (en) 2016-11-21 2019-09-03 艾里奥治疗公司 The transdermal delivery of big reagent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (en) * 1986-12-31 1991-04-19 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
AU3176097A (en) * 1997-06-13 1998-12-30 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0074658A1 *

Also Published As

Publication number Publication date
WO2000074658A1 (en) 2000-12-14
AU4373499A (en) 2000-12-28
JP2003501379A (en) 2003-01-14

Similar Documents

Publication Publication Date Title
WO2000074658A1 (en) Use of drug-loaded nanoparticles for the treatment of cancers
EP2262478B1 (en) Activated nitric oxide donors and methods of making and using thereof
US20100074927A1 (en) Delivery of therapeutic compounds via microparticles or microbubbles
US20110195030A1 (en) Nanoparticle compositions comprising liquid oil cores
EP2063881B1 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
KR100471672B1 (en) Microgranules containing cisplatin
AU2005284909B2 (en) Delivering iron to an animal
CN1139380A (en) Controlled release preparation
EA004943B1 (en) Suspension of biodegradable microspheres and method for treating gliobastoma
CN114469892A (en) Solvent evaporation method for preparing disulfiram-loaded nanoparticles
CN106061487A (en) Formulations for microparticle delivery of zinc protoporphyrins
JP5642892B2 (en) A combination containing macitentan for the treatment of glioblastoma multiforme
Yemisci et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres
WO2016020697A1 (en) Pharmaceutical compositions of polymeric nanoparticles
US20070042046A1 (en) Methods for the treatment of cancer
KR20200101577A (en) Microcarrier for Embolization and Preparation Method thereof
CZ20023333A3 (en) Medicament for treating cancer
Truter et al. Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5‐fluorouracil: toxicity against a rodent ovarian carcinoma in vitro
US20230225983A1 (en) Drug comprising plga nanoparticles loaded with cape targeted with angiopep-2 peptide
WO2007014150A2 (en) Method of administering liposomes containing oligonucleotides
Wahlberg et al. Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model
CN108392483A (en) A kind of preparation method and application of the albumin nano granular of paclitaxel plus 2ME2
Pandya et al. Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis
JP2022517352A (en) Liposomal Compositions and Production Methods Containing Liposomal Prodrugs of Mitomycin C
CN113045464A (en) Preparation, nano-drug, nano-particles and preparation method and application thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NANOPHARM AG

17Q First examination report despatched

Effective date: 20030516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040426

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1037962

Country of ref document: HK